Array Biopharma and Bristol Myers to work on colorectal cancer combo therapy

Array BioPharma Inc (NASDAQ:ARRY) has joined forces with Bristol-Myers Squibb Company (NYSE:BMY) to carry out clinical trials into a potential combination treatment for colorectal cancer.

Array will combine its investigational MEK inhibitor, binimetinib that can halt the growth of tumours. with Bristol-Myers’s immuno-ocology blockbuster Opdivo (nivolumab) and also Opdivo and Yervoy (ipilimumab).

Ron Squarer, Array’s chief executive, said: “Based on emerging data, we believe that studying combinations of targeted therapies, such as binimetinib, with immuno-oncology agents, such as Opdivo and Yervoy, could provide important scientific advances for patients fighting cancer.”

The Phase 1/2 study is expected to establish recommended dose regimens for further study and explore the preliminary anti-tumor activity of the combinations. Results from this first study will determine optimal approaches to further clinical development.

Array will organise the study with both companies providing financial support.

Story by ProactiveInvestors